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ASSOCIATED VIRUS 
MARK TIE 
 
ABSTRACT 
Recombinant adeno-associated viruses (rAAV) remain one of the most 
encouraging gene therapy vectors for treating patients with genetic abnormalities.  rAAV 
can safely deliver long-lasting expression of a therapeutic transgene to a wide range of 
cell types.  One challenge with therapeutic rAAV is the ability to generate enough virus 
for clinical trials and commercial supply. Doses administered systemically for 
neuromuscular or blood disorders can exceed 1 x 1014 viral genomes per patient. 
Approximate yields from a rAAV production are around 1 x 104 viral genomes per cell, 
meaning batch cell numbers would need to exceed 1 x 1010 for a single dose. This amount 
of therapeutic virus will require a production platform that can reliably generate sufficient 
quantities of therapeutic rAAV to meet patient demand.  Common expression platforms 
used in academia and industry are insufficient for generating this amount of virus, let 
alone in a controllable or reproducible setting.  More advanced systems based on stable 
cell lines paired with alternate viruses offer avenues for achieving more efficient 
production of virus, however there is no clear agreement on which system is most 
amenable to regulatory approval while also delivering safe and cost efficacious therapies 
to patients.  This paper will outline the basic biology of AAV and rAAV vectors.  The 
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common methods used to produce rAAV will be evaluated and a roadmap for producing 
clinical grade rAAV at scale will be provided.   
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PREFACE 
Working with living systems requires that biological understanding be paired with 
advanced technology and an ability to execute production in a robust manner.  Protein 
production manufacturing plants, based on mammalian expression systems, are multi-
billion dollar facilities and individual production campaigns can run into the millions of 
dollars.  The complexity of harnessing these living systems increases development, 
characterization and production costs to the point where promising therapies may be 
abandoned as commercially non-viable. The reemergence of gene therapy builds upon 
existing biologics production capabilities while creating a host of additional 
considerations.  The pricing model pertaining to protein biologics for chronic diseases 
often defers the revenue stream over years of repeat administration.  Gene therapies, in 
promising a cure, must recuperate the cost of development and production into what is 
likely to be a single administration or small number of doses (Brennan & Wilson, 2014).  
To realize the promise of gene therapy, the production method must be highly productive 
to constrain costs while maintaining consistent product quality; for the sake of regulatory 
approval and patient safety (Wright, 2008).   Given a standard per cell productivity, 
Table 1 lists the approximate cell culture volume or surface area required to achieve a 
given viral yield in suspension and adherent based systems.  The numbers are staggering 
when doses for systemically administered treatments may exceed 1x1014 viral genomes 
(Vg) per patient. 
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These figures suggest that the potential of the gene therapy field does not solely rest on 
the efficacy of the treatment; but is heavily contingent upon an ability to generate 
sufficient virus at a tractable cost.  The aim of this thesis is to provide a review of the 
available methods for producing rAAV as it specifically pertains to generating clinical 
grade, and quantities, of virus.  Academic and small industry groups can readily generate 
rAAV for research purposes and to power small clinical trials, however it will be shown 
that these methods are not suitable for powering large trials let alone approval and 
commercialization of a product.  Furthermore, small scale methods are neither robust nor 
regulatory compliant.  The literature surrounding more advanced stable cell line systems 
is sparse, and there is no consistent roadmap for groups looking to transition from 
Table 1. Volume and surface areas to achieve a given viral genome (Vg) yield. 
Assuming 1x10^4 vg/cell productivity, the volume of suspension and adherent 
dependent processes in order to achieve a given viral genome (VG) requirement is 
listed (Cecchini, Negrete, & Kotin, 2008).   
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promising pre-clinical candidates to the clinic and beyond.  This document will detail and 
evaluate the available methods, then provide a recommended workflow for how a group 
with a promising candidate therapy ought to build a commercial ready platform that 
would be suitable for meeting patient and market demands.      
  
  x
 
 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
ACKNOWLEDGMENTS ................................................................................................. iv 
ABSTRACT ........................................................................................................................ v 
PREFACE ......................................................................................................................... vii 
TABLE OF CONTENTS .................................................................................................... x 
LIST OF TABLES ............................................................................................................ xii 
LIST OF FIGURES ......................................................................................................... xiii 
LIST OF ABBREVIATIONS .......................................................................................... xiv 
Introduction ......................................................................................................................... 1 
AAV ................................................................................................................................ 1 
rAAV............................................................................................................................... 5 
rAAV Generation ................................................................................................................ 7 
Transient Transfection .................................................................................................... 8 
Herpes Simplex Virus ................................................................................................... 12 
  xi
Baculovirus ................................................................................................................... 18 
Producer and Packaging Cell Lines .............................................................................. 23 
Discussion ......................................................................................................................... 28 
REFERENCES ................................................................................................................. 36 
CURRICULUM VITAE ................................................................................................... 45 
 
  
  xii
LIST OF TABLES 
Table 1. Volume and surface areas to achieve a given viral genome (Vg) yield. ........... viii 
Table 2. AAV serotype tropism .......................................................................................... 5 
 
 
  
  xiii 
LIST OF FIGURES 
 
Figure 1. Wild type AAV genome ...................................................................................... 3 
Figure 2. Trafficking of AAV ............................................................................................. 4 
Figure 3. Transient transfection .......................................................................................... 9 
Figure 4. Plasmid delivery of Rep and Cap in HSV system ............................................. 14 
Figure 5. Herpes simplex virus and vector. ...................................................................... 16 
Figure 6. RAAV production system from HSV hybrid system. ....................................... 18 
Figure 7. AAV genome replicates in Sf9 insect cells. ...................................................... 19 
Figure 8. A three-viral seed stock baculoviral setup ......................................................... 21 
Figure 9. Insertion of a functional intron into the Rep and Cap AAV coding regions. .... 22 
Figure 10. The Producer Cell Line. .................................................................................. 24 
Figure 11. Conditional rep expression. ............................................................................. 25 
Figure 12. Single plasmid for generation of a PCL. ......................................................... 26 
Figure 13. Cassettes for integrating Ad5 helper functions into host cells. ....................... 28 
  
  xiv
LIST OF ABBREVIATIONS 
 
AAV ............................................................................................... Adeno-Associated Virus 
AAVS1 .................................................................. adeno-associated virus integration site 1 
AcNPV ............................................................. Autographa californica Polyhedrosis Virus 
Ad5 ........................................................................................... Adenovirus serotype-5 virus 
BHK ................................................................................................... Baby Hamster Kidney 
CHO ................................................................................................ Chinese Hamster Ovary 
CMV ........................................................................................................ Cytomegaolovirus 
CSTR................................................................................ Continuous Stirred-Tank Reactor 
GFP ..............................................................................................Green Fluorescent Protein 
GMP ....................................................................................... Good Manufacturing Practice 
GOI .............................................................................................................. Gene of Interest 
HEK ........................................................................................... Human Embryonic Kidney 
HPV................................................................................................. Human Papilloma Virus 
HSV.................................................................................................... Herpes Simplex Virus 
IEX ....................................................................................... ion-exchange chromatographic 
ITR ............................................................................................... Inverted Terminal Repeat 
mRNA ..................................................................................... Messenger Ribonucleic Acid 
NGNA ....................................................................................... N-glycolylneuraminic Acid 
PCL ......................................................................................................... Producer Cell Line 
PEI............................................................................................................. Polyethylenimine 
PTM .................................................................................. Post Translational Modifications 
  xv
rAAV........................................................................ Recombinant Adeno-Associated Virus 
Rf.................................................................................................................Replicative form 
ssDNA .................................................................... Single Stranded Deoxyribonucleic Acid 
UF/DF ........................................................................................ Ultrafiltration/Diafiltration 
UL ...................................................................................................................... Unique long 
US .................................................................................................................... Unique Short 
Vg ................................................................................................................... Viral genomes 
VP ..................................................................................................................... Viral Protein 
α-gal ............................................................................................... terminal-α-1,3-galactose 
 
  1
 
Introduction 
AAV 
Adeno-Associated Virus is a small non-enveloped single stranded DNA (ssDNA) 
virus belonging to the parvovirus family.  The virus was given its name as it was 
discovered as a contaminant alongside adenovirus infected monkey cells in the 1960’s 
(Atchison et al., 1965).  AAV is non-pathogenic, as it is not known to cause disease in 
humans, but still maintains the ability to infect a wide variety of cell types as is seen in 
Table 2. The lack of a pronounced immune response in humans (Mingozzi & High, 
2013), and diverse tissue tropism has made AAV a strong candidate as a gene therapy 
vector (Srivastava, 2016).  Further AAV has been known to lead to long term expression 
of transgene payload.   
Devoid of helper functions, the wild-type virus readily integrates into the adeno-
associated virus integration site 1 (AAVS1) locus on chromosome 19q13.42 and lead to 
long-term latency (Linden et al., 1996).  The targeting of this locus is directed by the Rep 
protein, encoded within AAV, and a consensus binding site in the human genome at the 
AAVS1 locus (Luo et al., 2017).  The virus is classified as a dependovirus and thus 
remains dormant until viral helper functions are presented by a second virus, often 
Adenovirus or Herpes Simplex Virus (HSV) (Geoffroy & Salvetti, 2005), which will 
transition the virus into a lytic phase (Hüser et al., 2010).  The proviral genome is excised 
from the genome, a function of Rep (Pereira et al., 1997), replicated as a double stranded 
replicative form (Rf), followed by single stranded viral gene expression which is 
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subsequently loaded into the capsid encoded by the Cap gene products (Lochrie et al., 
2006).   
The small single stranded genome of 4.7kb encodes two genes with three open 
reading frames flanked by inverted terminal repeats (ITRs) as can be seen in Figure 1.  
Like many viruses that have evolved over millennia with a high mutation rate, the 
genome is highly efficient and packages several overlapping reading frames.  The 
genome gains further efficiency by making use of splice variants to generate multiple 
mRNA transcripts and thus functional proteins with related but independent roles.    
The Rep gene contains two open reading frames driven by the native P5 and P19 
promoters (Weitzman et al, 1996).  The promoters generate the Rep78 and Rep 68 
transcripts and the Rep 52 and Rep40 transcripts, respectively.  The Rep68 and Rep40 are 
generated as splice variants as can be seen in Figure 1.  The genes themselves are named 
according to their protein molecular weight.  Rep genes are trans-activated by the 
presence of helper functions, chiefly E1A from Adenovirus.  The two larger transcripts 
are involved in regulatory and life cycle functions such as insertion and excision from the 
AAVS1 locus as well as DNA replication and modulation of host cell gene expression 
(Balakrishnan & Jayandharan, 2014).  The virus has evolved with human hosts, and thus 
viral gene functions additionally create a microenvironment suitable for viral purposes by 
creating a permissive environment for the viral life cycle.  Rep78 will specifically lock 
the host cell into the S-phase through hypophosphorylation of retinoblastoma and through 
DNA nicking at naturally occurring Rep binding sites ensuring that the appropriate 
genomic replication machinery is in abundant supply to support viral needs (Young et al., 
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2000).  The smaller two Rep proteins are known to have helicase functionality that is 
imperative for capsid loading during viral life cycle maturity.  Interestingly these two 
transcripts suppress P5 promoter activity in the absence of helper viral proteins (Pereira 
et al., 1997).   
 
The Cap Gene encodes the VP1, VP2, and VP3 genes that comprise the structural 
proteins of the Capsid (Rose et al., 1971).  The three transcripts are under control of the 
P40 promoter with two splice variants arising from downstream alternative ACG and 
canonical ATG start codons (Balakrishnan & Jayandharan, 2014) as is displayed in 
Figure 1.  The three transcripts, and their respective proteins comprise the icosahedral 
capsid that protects the viral genome and confers infectivity toward target cells.  The 
tropism of each serotype, shown in Table 2, is a product of the three-dimensional 
interaction of the capsid proteins and the respective composition of target cell receptors, 
some of which are not fully defined.  The capsid also plays a critical role in intracellular 
 
Figure 1. Wild type AAV genome 
The 4.7kb genome is comprised of three open reading frames producing a total of 
4 regulatory and 3 structural transcripts through alternative splicing and start 
codons.   
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trafficking.  Following endocytosis, the nuclear signaling domains of VP1 and VP2 are 
become exposed due to the acidic environment of the endosome (Nonnenmacher & 
Weber, 2015).  Further, endosomal escape is catalyzed by the exposure of a 
phospholipase A2 domain contained within VP1.  The ratio of proteins can vary based on 
serotype, but generally fall into a 1:1:10 ratio.    
 
Figure 2. Trafficking of AAV 
AAV gains cellular entry through binding of receptor and co-receptors based on 
the serotype specific capsid.  Entry is through endocytosis, endocytosis in 
clathrin coated pits, or caveolar endocytosis.  Viruses are traffic through early 
endosomes to late endosomes.  Acidification of endosomes exposes PLA2 and 
subsequent release from endosmal compartments and trafficking through 
nuclear pores.  Uncoating takes place in the nucleus (Nonnenmacher & Weber, 
2015). 
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The Rep and Cap genes are flanked by two 145 base pair inverted terminal repeat 
(ITR) sequences.  Each ITR contains a 125bp sequence that is self-complementary to 
itself and thus forms a hairpin structure with an unpaired 20 base pair D-sequence (Yan et 
al., 2005).  The free 3’ hydroxyl of the ITR forms the basis for second strand synthesis, 
which comprises the stable, double stranded expression competent complex.  A strand 
displacement model allows for single stranded genome replication as the viral life cycle 
commences in the presence of helper functions.   
 
rAAV 
Recombinant adeno-associated virus differs from wild-type AAV in several key 
ways that make it a versatile tool for gene delivery.  AAV is termed a gutless vector as 
the only element required to generate an infectious particle is the flanking ITRs in cis and 
the core of the wild-type viral coding regions, Rep and Cap, can be delivered in trans to 
actuate a system capable of replication.  The genome coded between the ITRs dictates the 
Table 2. AAV serotype tropism 
Multiple naturally found capsids are readily able to target a host of tissue types in 
humans (Srivastava, 2016).   
Serotype Tissue Target 
AAV1 Muscle, Heart, Eye, CNS 
AAV2 CNS, Kidney, Muscle 
AAV4 Lung 
AAV5 Lung, CNS, Eye, Pancreas 
AAV6 Lung, Heart 
AAV7 Muscle, Liver 
AAV9 Liver, Muscle, Eye, CNS, Heart 
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sequence to be packaged into the capsid in the presence of helper functions.  The 
packaging capacity of the plasmid is generally considered to be under 5kb (Wu et al., 
2010).  The various workable configurations of these elements and the respective 
biological systems will be discussed in subsequent sections.  The removal of Rep from 
the genome also alters the way the vector behaves in target cells.  Without Rep positioned 
within the ITRs, the vector will no longer target integration at AAVS1, and will instead 
be maintained as extrachromosomal units (Schultz & Chamberlain, 2008).  There are two 
competing models on how AAV creates stable double stranded conformationally stable 
units upon entering the nucleus (Nakai et al., 2000).  Capsid un-coating takes place 
immediately prior to, or simultaneous with transport into the nucleus (Lux et al., 2005).  
The first model is the second strand synthesis model suggests that the self-priming nature 
of the free 3’ hydroxyl of the ITR hairpin initiates complementary strand synthesis using 
host polymerases (Weitzman et al., 1996).   The competing view is that sense and 
antisense genomes, which are present in equimolar ratios, anneal together to form stable 
double stranded units (Nakai et al., 2000).  Unpaired single stranded genomes will be 
degraded over time, while double stranded units will circularize into monomeric or 
multimeric episomes.  The conformationally stable, double stranded, episomal structures 
are what confer long-term expression of genes transferred by rAAV in quiescent cell 
types (Duan et al., 1998).  One of the primary upsides of rAAV is the avoidance of 
disruptive genomic integration events that could lead to activation of oncogenes, or 
silencing of tumor suppressors.  To the contrary, rAAV is only effective in quiescent cells 
as the episomes would not replicate with cell division, and thus be present in 
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proportionally fewer cells with time, and finally be lost as the infected cells die or are 
eliminated.   
 
rAAV Generation 
Generation of rAAV requires three core inputs.  First, Rep and Cap are to be 
delivered in trans, meaning they will be removed from the AAV genome and provided 
externally to the two ITR sequences.  In the absence of helper functions, the three 
promoters driving the component transcripts will be silenced.  Second, the gene of 
interest is provided in cis, and thus replaces the wild type orientation of Rep and Cap 
between the ITR elements.  The in cis elements will be packaged into the capsid and thus 
compose the gene to be transferred by the vector.  The gene of interest must be driven by 
a promoter known to be active in the tissue type to be targeted by the therapeutic vector.  
Constitutive promoters, such as the human cytomegalovirus (CMV), are often the most 
powerful drivers of transcription.  However, AAV serotypes while somewhat specific, 
will often target multiple disparate tissues as is can be seen in Table 2.  It may be wise to 
sacrifice the potency of a CMV promoter for one that is specifically active in the disease 
tissue of interest, thereby abrogating untoward effects of the transgene in unintentionally 
targeted tissues (De Leeuw et al., 2016).  Third, secondary viral helper functions must be 
present to transactivate the three promoters and thus trigger the AAV life cycle and 
generation of packaging capsids (McLaughlin et al., 1988).   
As has been noted, the generation of rAAV requires a gene of interest in cis with 
the transgene, the viral Rep and Cap genes in trans, and additional viral helper functions.  
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There are four commonly used platforms that use varying configurations and thus confer 
different advantages and disadvantages.  Each group must take stock of their needs for 
speed and productivity and how those weigh against their abilities and laboratory 
technology.  Furthermore, some methods will be shown as more regulatory compliant and 
thus better choices for progressing therapeutics toward the clinic despite the additional 
complexity.  The next section will delve heavily into the four main configurations for the 
generation of rAAV and how they are suited for addressing the generation of clinical 
grade rAAV therapeutics.   
 
Transient Transfection 
 Many groups working with AAV in early development are most interested in 
generating small amounts of virus to work with and are less concerned with robustness or 
product quality.  The most direct method for generating rAAV is a transient transfection 
method often referred to as triple transfection.  A general view of this method is seen in 
Figure 3.    
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Figure 3. Transient transfection 
Three plasmids encoding the ITR flanked GOI, Rep and Cap, and helper functions 
are transfected into HEK293 cells.  AAV is generated from transient (non-
integrated) DNA transcription in the nucleus.  
 
This method involves mammalian cells, most commonly Human Embryonic Kidney 
(HEK) 293 cells.  HEK-293 cells were originally transformed by infection with 
adenovirus type 5, and thus contain the E1A and E1B sequences.  The consequence of 
E1A and E1B being integrated into the HEK-293 genome is that helper functions can be 
delivered with E1 deleted (E1∆).  This can take two forms.  The first, and less commonly 
used would be using E1∆ Ad5, which is a replication incompetent form of the virus.  Ad5 
is pathogenic, and thus an incompetent form of the virus is a preferable option from a 
safety standpoint, but also due to the burden placed on downstream purification and 
analytical assays to remove and validate clearance of the virus.  The more common 
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approach is to encode the helper functions onto a plasmid, without E1, and deliver it 
simultaneously with a plasmid encoding Rep and Cap, and another plasmid encoding the 
gene of interest flanked by ITRs (hence the term “triple transfection”).  Helper functions 
used in the transient system are most readily those cloned from Adenovirus, E1a, E1b, 
E2a, E4orf6 and VA RNA genes (Matsushita et al., 2004).   
The independent coding on separate plasmids allows transgenes, ITR elements 
and capsids to be interchanged more readily than with cell lines generated with these 
components integrated stably into the genomic backbone.  The transient nature means 
that researchers can rapidly generate material, albeit in small quantities.  The plasmids 
are commonly delivered using cationic lipids to HEK-293 cells.  Cationic lipids form a 
micelle surrounding the negatively charged plasmid DNA and the lipid bilayer which 
allows the complex to pass through the cell membrane (Safinya, 2001).  The complex 
traffics through lysosomal and endosomal compartments before transporting to the 
nucleus where transcription can take place.   
HEK-293 cells are most readily transfected as an adherent cell line grown in 
commercially available media supplemented with fetal bovine serum.  Adherent growth 
limits volumetric productivity by restricting biomass to the culture surface.  HEK cells 
can grow in suspension, serum-free conditions; but they are not readily transfected as a 
suspension cell line due to poorly understand changes in the physiology, and thus 
permissiveness of the cells upon suspension adaptation.  The adherent nature of this 
system greatly reduces the scalability of the system.  A promising method for exploiting 
the permissive nature of adherent cell lines while maximizing cell densities and thus 
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productivities is the use of microcarrier technology (Rafiq et al., 2017).  Microcarriers are 
small polystyrene beads with a cationic amine surface modification that make them 
amenable as surface substrates for anchorage dependent cell lines.  Cells adhered to 
microcarriers can be grown to high cell densities in continuous stirred-tank reactors 
(CSTR) all the while putatively maintaining their permissiveness to uptake of cationic 
lipids containing plasmid DNA.   
Currently there is not enough evidence for the microcarrier technology which 
renders triple transfection as an adherent system the predominant method.  The major 
drawback remains the difficulty in achieving scale and reproducibility, two elements 
critical for generating enough material of similar product quality to meet the rigorous 
standards for clinical applications.  An additional burden is the raw material 
requirements.  Transfection reagents, such as polyethylenimine (PEI), and plasmid DNA 
made in good manufacturing practice (GMP) environment are expensive when required 
for the 100’s or 1000’s of liter scale.  A standard method for scaling adherent cultures is 
to gravitate away from dishes and T flasks to hyper-stacks, where multiple layers of 
tissue culture plastic are stacked upon one another in a single vessel.  The extreme of this 
technology is the HS-36 which provides 18-square meters of tissue culture surface in a 
single vessel at a cost of several thousand dollars each.  These vessels also are burdened 
by multiple ports, air vents, and required manipulations for passaging and feeding.  Each 
of these steps, when multiplied across many replicate vessels, creates a high risk for 
contamination and thus costly production failures.   
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Herpes Simplex Virus 
 The necessity for large amounts of bio-comparable rAAV to power clinical trials 
has been addressed through the development and refinement of more scalable or stable 
cell line production platforms.  The replication deficiency for AAV, and rAAV, 
necessitates the presence of helper functions, primarily from Adenovirus.  However, 
adenovirus is not the only virus capable of providing the regulatory and 
microenvironment altering helper functions required for AAV generation.  The Human 
Papilloma Virus (HPV), Vaccinia virus and herpes simplex virus type-1 (HSV) can also 
confer the requisite helper functions (Wold & Toth, 2012).  The first two have not been 
explored as viable beyond their innate ability to confer helper functions (Schlehofer et al., 
1986).  HSV has a growing track record as a suitable hybrid method for generating AAV.  
HSV has a large doubled stranded linear 152kb genome comprising fewer than 100 genes 
(Blits & Bunge, 2006).  The viral icosahedral capsid is surrounded by a proteinaceous 
layer termed the tegument that itself is shielded by a lipid bilayer studded with 
glycoproteins (Akhtar & Shukla, 2010).  The genome itself is segmented into Unique 
Long (UL) and Unique Short (US) segments, and many of the HSV genes are non-
essential which enables transgenes to be readily inserted into the genome without 
hampering the critical effectiveness of the virus.  HSV-1 contains a set of genes, differing 
from those found in adenovirus, capable of regulating and stimulating the production of 
rAAV.  Within HSV, Weindler conducted mutation studies to identify the minimal set of 
genes required as UL5, UL8, UL52 and UL29 (Weindler & Heilbronn, 1991).  UL5, UL8 
and UL52 form an enzyme complex that has helicase and primase functionality, while 
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UL29 is a DNA binding protein.  It’s worth noting the differences between the regulatory 
nature of adenovirus helper functions and the DNA replication nature of HSV helper 
functions.   
 rAAV generation from the HSV platform can take many forms.  The earliest 
system developed is an amplicon system where the core of the AAV genome, with the 
capsid of interest are cloned into a plasmid also containing the HSV origin and packaging 
signal as can be seen in Figure 4 (Conway et al.,  1997).  The plasmid can be transfected 
along with wild-type HSV DNA or replication defective HSV itself to provide the trans 
helper functions required for generation of rAAV genome and packaging.  In the same 
paper Conway’s group showed that in the place of plasmid DNA containing the rAAV 
genome, rAAV virions and even rAAV genomes integrated into the host cell line are 
viable methods when complemented with the HSV helper functions.  
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From a raw materials perspective, the HSV amplicon system has several 
drawbacks.  First, HSV is highly pathogenic and thus creates a safety concern within the 
work environment, but also demands an active approach to viral management.  Robust 
purification methods must be instituted which will lead to concomitant reductions in 
rAAV yield.  Additionally, state of the art analytic techniques must be developed and 
applied to prove full removal of contaminating HSV virus.  The second complicating 
factor is the complexity of managing three precursors; HSV-RC, mutated HSV, and the 
source of the rAAV genome. 
The next iteration of the HSV/AAV system relies upon the generation of a 
recombinant HSV virus containing the requisite AAV genes.  Booth generated rHSV-
 
Figure 4. Plasmid delivery of Rep and Cap in HSV system 
Plasmid delivery of HSV origin of replication, Rep2 and Cap2, and alpha sequence 
that confers the packaging signal (Conway et al., 1997).     
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RC by way of a plasmid containing homologous sequences to the UL43 region of the 
HSV genome.  The homologous regions flanked the Rep/Cap genome sequence, 
respectively, allowing for homologous recombination (Booth et al.,  2004).  rAAV is 
generated by infecting Vero, BHK or HEK cells with the rHSV-RC and a plasmid 
containing the in cis gene of interest.  Booth found this system to be 100-times more 
productive than the straight amplicon system.   
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Figure 5. Herpes simplex virus and vector. 
Top: Wild type genomic locus for targeting showing the thymidine kinase gene 
and ICP27 gene. Middle: the rHSV-RC and rHSV-GOI genomes with disrupted TK 
and deleted ICP27 genes.  Bottom: Packaged rHSV virions (Clément et al.,  2009).   
  17
One of the current leading methods for rAAV production, by Conway’s group, 
furthers the hybrid method.  Rather than rely upon transfection to deliver any 
components, they generated two independent seed stocks, one rHSV-RC and one rHSV-
rAAV.  Both were inserted via homologous recombination into the thymidine kinase 
(TK) gene and thus provided a basis for selection using the toxicity associated with 
ganciclovir addition (Conway et al., 1999).  Simultaneously, the key HSV replication 
gene ICP27 was deleted rendering HSV replication incompetent.  The two viral seed 
stocks were propagated in Vero or V27 cells expressing HSV ICP27 to complement the 
viruses upon infection.  It should be noted that the sequestration of the two seed stocks 
conveys a beneficial level of flexibility for mixing and matching capsids and genes of 
interest that isn’t available in systems fully engineered with both components.  
Subsequently the two rHSV viruses were used to infect a final BHK cell line that was 
amenable to growth in suspension as is seen in Figure 6.  This method rarely produced 
replication competent, wild type, AAV, likely due to the partitioning of the cis and trans 
components during seed stock generation.   
  18
 
Figure 6. RAAV production system from HSV hybrid system. 
Two HSV viral seed stocks are generated in Vero cells.  The viral seed stocks infect 
BHK cells to generate rAAV using the HSV helper functions.  
 
Baculovirus 
 The necessity for helper functions is both essential for rAAV production, but also 
a burden for purification and yield considerations.  Another key element is the ability to 
grow and transfect, or infect, the cells used as a viral factory in suspension to concentrate 
enough cell mass into manageable vessels.  Researchers have been exploring viruses that 
infect insect cells, baculoviruses, as another approach for generating stable, highly 
productive clinical grade rAAV.  Insect cells, mainly Sf9 cells, readily grow to high 
densities in suspension, serum-free culture.  Despite their invertebrate phylogeny it has 
been shown that baculoviruses not only infect and propagate within insect cells but that 
the key AAV viral proteins are readily generated and functional within these cells 
(Madore et al., 1999; Christensen et al., 1994).   Figure 7 shows a key study by Urabe 
proving that baculovirus are readily able to propagate AAV structural proteins (Urabe et 
al., 2002). Thus, baculoviral systems based within the Sf9 cell type have been developed 
using similar strategies as the HSV system to generate rAAV.   
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Figure 7. AAV genome replicates in Sf9 insect cells. 
Southern blot showing that GFP-AAV genome can successfully be generated in the 
presence of Rep in SF9 cells.  The monomer is denoted as 1, with dimers and 
higher order structures denoted with 3-5.  Arrow denotes the input baculoviral 
genome (Urabe et al., 2002).   
 
 Like HSV, these systems require an in cis transgene cassette and trans AAV factors to 
catalyze the rAAV lifecycle.  Here, though, initial efforts focused on three individual 
viral seed stocks to be generated as can be seen in Figure 8, with the Rep, Cap, and Gene 
of interest residing on individual precursors.  Insect cells are not known to properly 
transcribe and process variants from overlapping open reading frames, so the Urabe 
group found it necessary to partition the p5 (Rep78 and Rep68) and p19 (Rep52 and 
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Rep40) coding sequences.  As was noted in the introduction, each of the two open 
reading frames produces two transcripts through one splice variant; hence single coding 
of the two full length transcripts is sufficient for generation of all four gene products and 
thus full activity of the regulatory machinery.   Many groups employ the Autographa 
californica polyhedrosis virus (AcNPV) in conjunction with Sf9 cells to generate rAAV.  
The system functions based on a strong p10 promoter which performs the analogous role 
to the CMV promoter in the producer cell line.  The p10 has strong activity and can drive 
transgene sequences.   
A paramount concern when using an invertebrate cell line for generation of 
biotherapeutics is the effect of using non-mammalian cells on post translational 
modifications (PTMs), such as O-linked and N-linked glycosylation, gamma-
carboxylation, and phosphorylation.  For standard protein therapeutics, these attributes 
are intricately involved in bioactivity, stability, clearance, and interaction with the 
immune system.  PTMs are the primary reasons why complex mammalian expression 
systems are warranted in lieu of fast growing, inexpensive bacterial systems.  While the 
critical quality attributes for rAAV are not well defined for rAAV therapies; concern 
regarding the potential immunogenicity of viral particles is a central focus of researchers 
and regulators (Thacker, 2009).  Biotherapeutics produced in human cells are the least 
likely to confer an immune-reactive PTM.  It would reason that swapping to an 
invertebrate system, despite the advantages, would warrant additional purity and PTM 
analytical package validation and scrutiny from regulatory agencies.   
  21
 
Figure 8. A three-viral seed stock baculoviral setup 
Top: The Rep delivery, of note only a single gene product from the p19 and p5 
promoters is necessary.  Middle: The viral capsid cassette containing the insect 
cell polyhedrin (polh) promoter.  Bottom: the ITR (black box) flanked gene of 
interest; green fluorescent protein (GFP) (Urabe et al., 2002).   
 
 As previously mentioned, insect cells are not known to express from overlapping 
open reading frames.  As Figure 1 shows, the p19 promoter is embedded in the coding 
region of the p5 Rep78 and Rep68 major gene products.  The Urabe group initially 
overcame this limitation by partitioning the p5 and p19 gene products, as a continuous 
intact coding sequence.   It was found in passaging studies of the individual seed stocks 
that the titer of Bac-Rep declined steadily with serial culturing suggesting that the head-
to-tail Rep78 and Rep52 orientation was not stable and this led to a direct reduction in 
overall rAAV productivity (Kohlbrenner et al., 2005).  A single intron was identified in 
the IE-1 gene of AcNPV that appeared to be functionally processed in Sf9 cells.  Figure 9 
shows an elegant setup where the Chen group inserted this intron with part of the 
polyhedron promoter into the Rep and Cap genes allowing for a single Baculoviral 
sequence for each component and realized normalized stability with high level expression 
system.   
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Figure 9. Insertion of a functional intron into the Rep and Cap AAV coding 
regions. 
Top: The polh intron inserted into Rep gene enabling a single coding sequence to 
maintain both Rep78 and Rep52 transcripts which can further be spliced to the 
minor Rep68 and Rep40 gene products.  Bottom: The polh intron inserted into the 
capsid coding sequence with wildtype canonical and alternate stop codons 
maintains expression of all three VP gene products (Chen, 2008).   
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Producer and Packaging Cell Lines 
 Production of biotherapeutics is most commonly performed in mammalian cell 
lines.  Mammalian cell lines can be grown in suspension to high cell densities and will 
confer, depending on the cell line chosen, less immunogenic post-translational 
modifications.  However, even within accepted practices, Chinese Hamster Ovary (CHO) 
cells are the mainstay of protein therapeutic expression systems, the various lineages 
(dg44, CHOK1, CHO-S) confer non-human N-glycolylneuraminic 
Acid (NGNA) and terminal-α-1,3-galactose (α-gal) immunogenic epitopes.   These 
epitopes must be rigorously characterized and screened out during cell line development 
activities (Berkowitz et al., 2012).  The gene therapy field has been restricted to a small 
number of viable cell line options, requiring a human cell line capable of high levels of 
transgene expression, an ability to grow in suspension serum-free conditions, all without 
imposing tumorigenic risk.   
The producer and packaging cell lines are a modified extension of stable 
antibody, and protein, therapeutic cell lines.  Packaging cell lines integrate the Rep and 
Cap sequences into a production host cell line’s genomic DNA.  The host cell then relies 
upon the delivery of the rAAV genome through transfection with the simultaneous 
infection of a wildtype human Adenovirus serotype-5 virus (Ad5), or an infection of 
recombinant Ad5 containing the rAAV genome of interest as a payload.  Producer cell 
lines (PCL) integrate the Rep, Cap, and rAAV genomes into the genomic backbone as 
can be seen in Figure 10.  
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Figure 10. The Producer Cell Line. 
Rep, Cap, and the transgene in cis are integrated into the genomic backbone of a 
mammalian cell line, here HeLa S3.  Ad5 infection triggers AAV production as well 
as additional Ad5.  
 
In the absence of helper functions, the PCL will not generate rAAV and thus 
mimics the latent phase of an AAV infection in nature.  The p5 and p19 promoters will be 
silent and thus the productive lifecycle of the virus cannot begin.  This is advantageous, 
as AAV generation and Rep activity are known to be toxic to host cells.  Interestingly, 
HEK cells are not a good substrate for the generic PCL setup.  As previously mentioned, 
HEK are transformed with adenoviral E1a and E1b which transactivate the p5 Rep gene 
leading to toxicity (Pereira et al., 1997).  The level of toxicity prohibits the accumulation 
of sufficient healthy cell mass using the HEK background to make it a viable system 
without instituting some level of conditional repression of the Rep protein.  One novel 
example of conditional rep expression is shown in Figure 11 (Qiao et al.,  2002).  Placing 
conditional repression on the p5 promoter does not silence the p19 activity and 
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subsequent toxicity due to the presence of a binding site for the E1a protein (Chang et al., 
1989).  The Qiao group navigated this pitfall by interrupting p19 expression with potent 
disruption of gene expression comprised of multiple poly-A termination signals and a 
hygromycin cassette all flanked by LoxP sites.  Cre recombinase expression delivered as 
a recombinant E1 deleted Ad5 loops out the cassette allowing for normal expression of 
the p5 and p19 Rep gene products and thus initiation of the rAAV viral life cycle 
 
Figure 11. Conditional rep expression. 
LoxP sites flanking a poly-A and hygromycin expression cassette.  Cre expression 
removes the sequence intervening the LoxP sites rescuing functional Rep and Cap 
expression of gene products (Qiao et al., 2002) 
 
 The two cell types most commonly used in PCL and packaging cell lines are the 
HeLa and A549 transformed cell lines.  HeLa is an immortalized human cervical 
carcinoma cell line and A549 is a human adenocarcinoma cell line.  HeLa is one of the 
most common cell lines used in academic and industrial settings.  HeLa has portions of 
the HPV-16 genome integrated; which may be one reason that no approved 
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biotherapeutics, aside from vaccines, have been generated in this cell line.  One 
advantage to these two cell lines is that, unlike in insect cells, normal splicing is 
functional in mammalian cell lines; allowing for integration of the intact AAV Rep and 
Cap genes.  CHO cell lines, despite their coveted status as a protein platform workhorse, 
are not thought to be useful as an AAV production platform.  The PCL system relies 
upon delivery of helper functions by human Ad5 virus which enters the cell using the 
coxsackievirus receptor (CAR) (Tomko et al., 1997).  The CAR receptor is not 
meaningfully present on CHO cells meaning this key step in production will be highly 
attenuated.  The inability of Ad5 to infect CHO as efficiently as these human lines has 
further bolstered the use of HeLa and A549 as PCL substrates.   
 The recombinant PCL is generated by transfecting either two plasmids, one 
containing the Rep and Cap native sequences and another with the gene of interest 
cassette in cis with the ITRs, or commonly a single plasmid containing these elements as 
is seen in Figure 12 (Martin et al., 2013).  Integration will be a random event with no 
known preference for the AASV1 locus.   
 
Figure 12. Single plasmid for generation of a PCL. 
Res: Gene for selection of transfected cells.  Prom: Promoter.  GOI: Gene of 
interest.  pA: PolyA tail.   
   
Caution must be taken to ensure overlap between the sequences do not provide an 
opportunity for recombination which can lead to the generation of wild type AAV in 
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vitro.  Stable cell lines are established by the application of an antibiotic agent in 
conjunction with the presence of a selective gene on the plasmid.   
 rAAV production is catalyzed by the delivery of helper functions, which does not 
in principal exclude strains of virus other than Ad5.  Ad5 is the primary choice for 
several reasons.  Ad5 readily infects human cells; key for AAV production in human cell 
lines, but also for generation of Ad5 as a raw material.  Ad5 is a precursor in the PCL 
process and it can be readily made at high titers in the same A549 or HeLa background 
used to generate the PCL.  Ad5 is also more heat labile than AAV providing the basis for 
selectively inactivating Ad5, as opposed to rAAV, in a post-production processing step.   
 Ad5 E1a transactivates the silent p5 promoter initiating AAV viral gene 
production to pair with the constitutive expression of the gene of interest (Weitzman et 
al., 1996).  Ad5 also has a dramatic effect on the host cell, and prepares the 
microenvironment for viral production at the expense of cellular functions beneficial to 
the host cell (Defer et al., 1990).  Ad5 will force the host cell into S-phase and therefore 
ensure replication machinery is abundant for genome replication.  E2a plays a role in the 
replication centers, E4 is involved with AAV replication and second strand synthesis, 
while the viral associated RNA induces expression of AAV regulatory and structural 
proteins (Balakrishnan & Jayandharan, 2014).  The presence of Ad5 creates a burden as a 
precursor and a byproduct.  The production of Ad5 as a byproduct during rAAV 
generation consumes cellular resources that would be better focused toward generation of 
the therapeutic.  The industry is turning toward integrating the key Ad5 helper functions 
into host cells which are used to develop PCL manufacturing lines (Qiao et al.,  2002).   
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In the system developed by Qiao, VA RNA, E2A and E4 are allowed free expression as 
they are not known to be toxic to host cells and do not activate AAV viral genes.  E1A 
and E1B are placed under the control of a tetracycline response element, maintaining 
tight repression until tetracycline or an analogue, commonly doxycycline, is added to the 
cell culture media and activates expression. The cassettes used to generate these cell lines 
are shown in Figure 13. 
 
Figure 13. Cassettes for integrating Ad5 helper functions into host cells. 
Top: E1A and E1B are placed downstream of a CMV promoter under control of a 
tetracycline response element (TRE).  Bottom: VA, E2A and E4 are not repressed 
as they do not toxic to host cells (Qiao, Li, et al., 2002). 
 
Discussion 
 rAAV approaches to gene therapy are reemerging as relevant vectors for gene 
transfer to patients suffering from diseases caused by genetic abnormalities.  The low 
immunogenicity of AAV, ability to target a wide variety of cell types and capacity to 
confer long term high levels of gene expression in target cells are the primary reasons 
rAAV is one of the most promising gene therapy vectors.  Unlike with recombinant 
proteins, generation of sufficient quantities of the therapeutic to treat diseases with 
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systemic administration is a formidable challenge.  Neuromuscular disorders may require 
greater than 1x1014 Vg per patient.  The complexity, and thus cost, of generating virus 
goes well beyond standard protein based therapeutic platforms.  The more advanced 
systems require complex management of raw materials and precursors beyond cell 
culture media and a single GMP cell bank.  Viral risk management of precursor, or 
byproduct, viruses further add expensive downstream costs.  Gene therapy production 
costs will exceed that of small molecule and protein therapeutics, which already pose as a 
contentious political and public health issue.   
 The most realistic method for containing cost will be choosing the most 
productive method of rAAV generation possible.   The four methods discussed differ 
greatly in their productivity profiles and scalability.  The two most productive platforms 
appear to be the baculoviral and the PCL.  Reports for both suggest that 1x1013-1x1014 
vg/L are obtainable, though the evidence cited are sparse and the gene of interest in each 
study is likely to play a profound role on productivity (Clément et al., 2009; Martin et al., 
2013).  Beyond simple per cell productivity, is the ability to scale the cell line into large 
single use disposable vessels, primarily stirred tank bioreactors to maximize rAAV 
volumetric productivity during costly production runs.  Many of the transient systems, 
short of expensive and unproven microcarrier technology, are adherent based as is the 
viral precursor generation for rHSV; despite the production run taking place in a BHK 
suspension cell line.    The baculovirus and PCL systems are realistically the only two 
systems that can operate end-to-end in suspension bioreactors.    
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The bioreactor environment enables high cell growth, but also robust control over 
the cell culture environment through a mixture of online and offline monitoring of cell 
growth (overall cell mass, viable cell density, cell viability), dissolved gas and acidity of 
culture medium (dissolved oxygen, CO2, pH), and metabolic inputs and waste products 
(glucose, glutamine, glutamate, ammonia, lactate).  Key nutrients can be fed back in 
using concentrated feeds or isolated inputs such as glucose, glutamine or base to maintain 
key parameters within optimized ranges.  Monitoring and control allows optimal growth 
conditions to be identified and banded for production runs enabling reproducible batches, 
but also providing a basis for rejection criteria for batches that deviate from normal and 
expected conditions.   The precise product quality attributes that will be scrutinized by 
regulatory authorities are not well-defined, as approved therapies administered directly to 
humans are lacking.  Presumably the ratio of empty to full particles, the ratio of the 
capsid proteins, and the amount of non-intended DNA packaged (host cell or plasmid 
derived) will be important. Post translational modifications as assessed by mass-
spectroscopy will assuredly build greater understanding around which quality attributes 
are important, and how consistent production platforms and processes apply them.  The 
baculovirus system may be a risky choice should the insect cells confer immunogenic 
epitopes to the viral capsid.  Even BHK, mammalian cells, will need to provide “absence 
of” evidence for PTMs should regulators gain comfort with human cell line production 
systems.  Historical perspective for biotechnology therapeutics would suggest that 
reproducibility will be an additional highly scrutinized aspect during regulatory vetting.  
The production system, and the use of highly controlled production vessels will be the 
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best mitigation strategies.    Transient and HSV systems in full, or in-part, will again fall 
short as adherent cultures, regardless of their scale are largely uncontrolled.   
Another consideration of high importance to regulatory bodies is the presence of 
animal derived products in the derivation or production process.  Adherent cells are 
generally grown in the presence of fetal bovine serum (FBS) on tissue culture-treated 
plastic.  Adherent growth vastly reduces the number of cells that can be grown in a 
vessel, which becomes further restricted by incubator space.  But most importantly, 
serum is looked upon with great skepticism by regulatory bodies due to the potential for 
contaminating adventitious viruses to be transferred from the animal derived raw material 
to the therapeutic.  Mammalian based protein therapeutics which have a much broader 
track record with regulatory approvals, are often generated in Chinese Hamster Ovary 
(CHO) cells adapted to grow in animal component free media.  Industry groups with cell 
culture focused groups can generate fully chemically defined cell culture media that 
allow for reproducible formulations with consistent control over raw materials.  
Complexity of precursor management will have an impact on the likelihood of 
success as well as the cost of the generation of material.  The cost of plasmid and 
transfection reagents for the transient method makes this method unrealistic for any scale 
beyond the laboratory bench.  rHSV and baculovirus systems too have biological 
precursors that must be generated in large quantities to initiate large scale production 
runs.  Baculoviral systems have further been plagued by instability of Rep containing 
recombinant viruses.  Only recently have genomic engineering solutions begun to show 
that this may be a tractable issue.  
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   This leaves the PCL as the most realistic platform for meeting the needs of 
a clinical grade rAAV production system.  The PCL is easily scaled as a suspension cell 
line in animal component free media.  As a human derived cell line, the likelihood of 
immunogenic epitopes being conferred onto the viral capsid are unlikely.  HeLa and 
A549 are tumorigenic cell lines.  Therapeutics generated in these cell lines will have to be 
thoroughly vetted to ensure that the unwanted tumorigenic sequences do not end up 
packaged into the capsid.  Considering the size of the genome, this seems like an unlikely 
scenario, however analytical methods such as Next Generation Sequencing should be 
able to readily identify and quantify contaminating DNA.  The other major drawback to 
PCL is the use of pathogenic Ad5 virus to initiate production.  This is problematic, but as 
will be detailed there are methods to clear Ad5 from the drug product stream.  As was 
discussed there are methods to engineer the key helper functions in an inducible system 
into the host cells.  The major drawback to the PCL system is the time required to 
generate the cell lines and the lack of flexibility a single cell line with the viral AAV 
genes and gene of interest has.  Disease indications requiring small amounts of virus, 
such as those directly administered to the ocular compartment, may not require the 
scalability, and thus upfront time and resource commitment, intrinsic to this system.   
In practice, the PCL is a logical extension of existing protein therapeutic 
workflows for generation of the stable cell line and execution of the production runs.  
What follows will be guidance on the practical attributes of how the execution and 
downstream steps may unfold to generate clinical material.   
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Production runs would begin with the thaw of the PCL cell line in a viral free 
environment and grown up in iteratively larger combinations of shake flasks, wave bags 
or CSTR bioreactors.  As the scale increases, centrifugation of cell culture becomes 
impractical (and is generally not used at all in production facilities at any stage).  The 
bioreactor prior to the production run, termed an N-1 reactor, may employ a modified fed 
batch or a perfusion reactor to achieve sufficient cell densities to seed the production 
reactor at the highest cell density that will support rAAV production.  These N-1 steps are 
critical to keeping the volume of cell culture transferred to the production reactor as 
minimal as possible.  This will reduce transfer of inhibitory waste products and maximize 
the proportion of fresh media in the production vessel.  The N-1 inoculum will be 
transferred to a designated viral suite where the Ad5 viral bank will be thawed and 
inoculated into the production reactor to a specific multiplicity of infection (MOI) 
containing acclimated PCL cells at the intended density.   The N-1 and production, but 
realistically all, vessels will be single use disposables.  The current maximum scale of 
single use bioreactors caps this process at 2000L, though various commercial suppliers 
may push this scale larger as the industry demands higher scale.  The production run 
generally unfolds over several days with minimal feed and nutrient additions, or pH 
adjustments as required.   
 Harvest conditions will be contingent on the viability of cells and how the 
respective capsid dictates the virus will be partitioned as some serotypes are retained in 
the cell while some are secreted.  A lysis step may be necessary in conjunction with an 
enzymatic digestion of free DNA from lysed host cells or unpackaged AAV or Ad5.  Cell 
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debris is most easily removed through depth filtration, which is followed by a buffer 
exchange and concentration step using ultrafiltration and diafiltration (UF/DF) to prepare 
the production stream for purification.   
Purification steps can be sequenced interchangeably, and in principal are dictated 
by the binding properties of the various loading and elution buffers to maximize yield off 
each step.  Prior to, or after, UF/DF an ion-exchange chromatographic (IEX) step to 
exploit the charge difference between the two viruses present can provide upfront 
meaningful removal of Ad5.  The two critical purification steps are a subsequent Anion 
Exchange (AEX) and affinity based chromatography.  The AEX step will exploit the 
charge difference conferred upon full rAAV capsids by the presence of a negatively 
charged genome.  This difference allows for resolution of empty and full particle.  Full 
particles can represent equal or greater quantities of the virus produced depending on the 
serotype and system chosen, and thus would represent an undue challenge to a patient’s 
immune system (Gao et al., 2014).  While there is no clear regulatory guidance for the 
level of full capsids warranted, a robust removal step must be developed.  Affinity 
chromatography exploits serotype specific binding to the capsid and thus removal of 
extraneous proteins and debris.  As previously mentioned a heat inactivation step also 
must be implemented to further inactivate Ad5 and undetected adventitious virus, and 
thus provide an orthogonal method for Ad5 removal.  The final step will employ UF/DF 
to formulate the affinity eluate to a buffer compatible for stability and administration to 
the compartment of the body the drug is intended for.   
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Gene therapy using rAAV is reemerging as one of the most promising therapeutic 
vectors for addressing a host of devastating genetic diseases.  rAAV is not known to 
cause pathology in humans, can infect a host of disparate cell types and has been shown 
to lead to long lasting expression of a transgene.  Large quantities of virus will be needed 
to dose patients intravenously or into central nervous system compartments.  The 
methods widely used by groups working in this field, primarily the transient transfection 
system, are insufficient in terms of productivity or robustness.  The transient and HSV 
systems rely on poorly scalable adherent systems that require problematic animal derived 
products.   The HSV and baculovirus systems require complex management of precursor 
viruses and plasmids.  The baculovirus system is marred by precursor instability and 
questions regarding post translational modifications.   The PCL system requires a long 
development time line; however, it avoids the pitfalls that afflict the other systems.  The 
PCL is scalable as a suspension line, can be grown in chemically defined serum-free 
media and requires only two precursors; Ad5 and the PCL itself.  The PCL is likely to be 
looked upon well by FDA regulators do to its foundation in protein production system 
technology that has been embraced by regulatory bodies for decades.  It’s hopeful that 
companies moving gene therapy candidates toward the clinic will embrace highly 
productive and physiologically reproducible systems.   This will be critical to contain 
costs for an already strained healthcare industry and thus ensure the promise of gene 
therapy becomes a reality for patients suffering from debilitating diseases.   
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